Management of early and locally advanced cervical cancer.

Abstract:

:Cervical cancer is the second most common malignancy in women and the third most common cause of cancer mortality worldwide. While primary and secondary preventions exist, the lack of widespread adoption leaves the treatment of cervical cancer an important oncologic problem. In this article, the management of early and locally advanced cervical carcinoma is reviewed, including staging, imaging, prognostic factors, and primary and adjuvant therapy and their outcomes.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Barbera L,Thomas G

doi

10.1053/j.seminoncol.2008.12.007

subject

Has Abstract

pub_date

2009-04-01 00:00:00

pages

155-69

issue

2

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(08)00264-9

journal_volume

36

pub_type

杂志文章,评审
  • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

    abstract::The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2017.08.004

    authors: Capoluongo E,Ellison G,López-Guerrero JA,Penault-Llorca F,Ligtenberg MJL,Banerjee S,Singer C,Friedman E,Markiefka B,Schirmacher P,Büttner R,van Asperen CJ,Ray-Coquard I,Endris V,Kamel-Reid S,Percival N,Bryce J,Röthlisbe

    更新日期:2017-06-01 00:00:00

  • Induction of apoptosis by gemcitabine.

    abstract::Inhibition of cellular DNA synthesis is the major action of gemcitabine. In cells, this drug is converted to its triphosphate (dFdCTP), which is incorporated into DNA and terminates DNA strand elongation. After incorporation of gemcitabine nucleotide into the DNA strand, one more deoxynucleotide is incorporated, and t...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Huang P,Plunkett W

    更新日期:1995-08-01 00:00:00

  • Descriptive epidemiology and risk factors for head and neck cancer.

    abstract::Although more common in developing countries, over 11,000 deaths will occur in the United States from head and neck cancer in 2004. Squamous cell carcinomas account for the vast majority of cases in the United States and the majority of these are related to exposure to tobacco and alcohol. Newer data suggest a genetic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.013

    authors: Sturgis EM,Wei Q,Spitz MR

    更新日期:2004-12-01 00:00:00

  • Ifosfamide in the treatment of bladder cancer.

    abstract::Although chemotherapy for advanced bladder cancer has historically been based on cisplatin-based combination regimens, the limitations of these regimens both in terms of efficacy and toxicity are now widely appreciated. In response to these limitations, other single agents have been studied, and a number have demonstr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Roth BJ

    更新日期:1996-06-01 00:00:00

  • Pathologic staging of melanoma.

    abstract::The American Joint Committee on Cancer (AJCC) recently launched a new staging system for cutaneous melanoma that was based on clinical experience with a large number of patients treated in major centers worldwide. As this system includes various histopathologic parameters of the primary melanoma and of melanoma metast...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.34116

    authors: Ruiter DJ,Spatz A,van den Oord JJ,Cook MG,Pathology Committee of the European Organization Research and Treatment of Cancer (EORTC) Melanoma Group.

    更新日期:2002-08-01 00:00:00

  • Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel-based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubic...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kennedy MJ,Donehower RC,Rowinsky EK

    更新日期:1995-08-01 00:00:00

  • Cardiac testing to manage cardiovascular risk in cancer patients.

    abstract::Cardiovascular toxicity is one of the most feared complications of cancer treatment. Recent advances in oncologic therapies have resulted in improved cancer outcomes but also a new set of cardiovascular adverse effects. Common toxicities include left ventricular dysfunction/heart failure, hypertension, and myocardial ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.01.003

    authors: Davis M,Witteles RM

    更新日期:2013-04-01 00:00:00

  • Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?

    abstract::Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Saltz L,Janik JE

    更新日期:1997-02-01 00:00:00

  • Small cell carcinoma of the lung: cellular origin and relationship to other neoplasms.

    abstract::Many small cell carcinomas share morphological and physiological characteristics with normal and neoplastic cells of Pearse's APUD series, including pulmonary APUD cells and pulmonary carcinoid tumors. There is very likely more than one type of APUD cell in the lung, and conclusions that small cell carcinomas and carc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tischler AS

    更新日期:1978-09-01 00:00:00

  • Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.

    abstract::The ability of dexrazoxane (DEX) to protect against doxorubicin (DOX)-induced cardiomyopathy has been demonstrated in mice, normotensive and hypertensive rats, rabbits, dogs, swine, and humans. These animal models of DOX-induced cardiomyopathy were found to be highly predictive of DEX activity clinically. In mice admi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Imondi AR

    更新日期:1998-08-01 00:00:00

  • Prognostic models in melanoma.

    abstract::Predicting which patients with primary melanoma are at risk of developing metastastic disease is important for making rational therapeutic decisions. Tumor thickness alone is the most commonly used predictor of survival, but other clinical and pathologic variables also play an important role. We have developed two mul...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Halpern AC,Schuchter LM

    更新日期:1997-02-01 00:00:00

  • Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies.

    abstract::Compelling data implicate angiogenesis and tumor-associated neovascularization as a central pathogenic step in the process of tumor growth, invasion, and metastasis. These complex processes involve multiple steps and pathways dependent on the local balance between positive and negative regulatory factors, as well as i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Pluda JM

    更新日期:1997-04-01 00:00:00

  • Combination paclitaxel and platinum in the treatment of lung cancer: US experience.

    abstract::Despite marked improvements in the treatment options available for patients with lung cancers, more than 85% of patients ultimately relapse and die of their disease. Among the most auspicious of new agents available to treat lung cancers, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) also has been th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bunn PA Jr

    更新日期:1996-12-01 00:00:00

  • Management of hormone-resistant prostate cancer: an Australian trial.

    abstract::The management of metastatic prostate cancer that has relapsed after initial hormonal manipulation remains a major problem, with the majority of patients dying within 12 months. Their clinical course is frequently characterized by progressive debilitation, pain, and other tumor-related symptoms. A phase II, non-random...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Raghavan D,Coorey G,Rosen M,Page J,Farebrother T

    更新日期:1996-12-01 00:00:00

  • MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.

    abstract::Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases. Deregulated activity of the Raf/MEK/ERK pathway drives uncontrolled ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.09.023

    authors: Wu PK,Park JI

    更新日期:2015-12-01 00:00:00

  • Practical considerations in the evaluation and management of adrenocortical cancer.

    abstract::Adrenocortical cancer (ACC) is a rare, challenging disease with a broad range of clinical presentations. Often presenting in an advanced stage with a large, locally invasive primary tumor or with Cushing's syndrome, it requires a multidisciplinary approach to treatment. We discuss controversies in the evaluation and m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.10.011

    authors: Balasubramaniam S,Fojo T

    更新日期:2010-12-01 00:00:00

  • The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

    abstract::For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.018

    authors: Robert NJ,Vogel CL,Henderson IC,Sparano JA,Moore MR,Silverman P,Overmoyer BA,Shapiro CL,Park JW,Colbern GT,Winer EP,Gabizon AA

    更新日期:2004-12-01 00:00:00

  • Clinical trials with ifosfamide: the Indiana University experience.

    abstract::At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

    更新日期:1992-02-01 00:00:00

  • The use of ondansetron in patients receiving multiple-day cisplatin regimens.

    abstract::The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:1992-08-01 00:00:00

  • Myeloma: classification and risk assessment.

    abstract::Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a deta...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.07.002

    authors: Fonseca R,Monge J

    更新日期:2013-10-01 00:00:00

  • A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.

    abstract::This phase I study was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) with standard doses of cisplatin and etoposide for patients with untreated, extensive-stage small cell lung cancer. Secondary objectives were to determine the toxicities, response ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bunn PA Jr,Kelly K

    更新日期:1997-08-01 00:00:00

  • Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.

    abstract::This article summarizes the likely attenuation properties of RRx-001 in COVID-19 based on its mechanism of action and the putative pathogenesis of the disease, which appears to activate inflammatory, oxidative, and immune cascades with the potential to culminate in acute respiratory distress syndrome, cytokine storm a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2020.07.002

    authors: Oronsky B,Knox S,Cabrales P,Oronsky A,Reid TR

    更新日期:2020-10-01 00:00:00

  • Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.

    abstract::Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful. Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurri...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90035-1

    authors: Falardeau P,Champagne P,Poyet P,Hariton C,Dupont E

    更新日期:2001-12-01 00:00:00

  • Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.

    abstract::We report an open, three-armed, multicenter study being carried out to assess the optimum treatment for acute and delayed emesis and nausea in patients undergoing highly emetogenic chemotherapy. Eighty-seven patients were randomized to receive tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), tropisetron p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Bruntsch U,Drechsler S,Eggert J,Gosse H,Ukena D,Imhoff W,Faerber L

    更新日期:1994-10-01 00:00:00

  • Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study.

    abstract::A trial of combination chemotherapy using mitoxantrone-cyclophosphamide was started in 1983. Sixteen patients with widely metastatic cancer of the breast, including one man, received mitoxantrone, 10 mg/m2 intravenously (IV) over 30 minutes on day 1, followed by cyclophosphamide, 200 mg/m2 by mouth (PO) daily in divid...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: McDonald DB,Abu-Zahra H,Yoshida S,Binder H

    更新日期:1984-09-01 00:00:00

  • Early studies of etoposide phosphate, a water-soluble prodrug.

    abstract::Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not saturable in humans at doses between 50 and 1,600 mg/m2. The resultant eto...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Budman DR

    更新日期:1996-12-01 00:00:00

  • Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.

    abstract::Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products incl...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31524

    authors: Arteaga CL,Khuri F,Krystal G,Sebti S

    更新日期:2002-02-01 00:00:00

  • Surgical treatment for gastric cancer: the Japanese approach.

    abstract::Present status of gastric cancer surgery in Japan and several new procedures are reviewed in this article. Japanese treatment results of this disease were significantly better than Western results even when stages were adjusted. Generally speaking, Japanese surgical procedures are more aggressive and meticulous compar...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Maruyama K,Sasako M,Kinoshita T,Sano T,Katai H

    更新日期:1996-06-01 00:00:00

  • Management of borderline tumors of the ovary: state of the art.

    abstract::Evidence published during several decades has shown that there is a group of epithelial ovarian tumors having histological and biological features between those of clearly benign and frankly malignant tumors. In 1963, FIGO accepted an intermediate group of ovarian carcinomas of low malignant potential. In 1973, WHO ad...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tropé C,Kaern J

    更新日期:1998-06-01 00:00:00

  • Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.

    abstract::Bendamustine has clinical potential in the treatment of low-grade non-Hodgkin's lymphoma (NHL). As a single agent, bendamustine has been used in two studies in patients with relapsed or refractory low-grade NHL. When bendamustine 120 mg/m(2) was given on days 1 and 2, the overall response rate was 73% with complete re...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.34877

    authors: Rummel MJ,Mitrou PS,Hoelzer D

    更新日期:2002-08-01 00:00:00